Overview
DeciBio Consulting is a life sciences-focused strategy firm that provides market analyses, commercial strategies, and growth plans for clients from startups to Fortune 500 companies. It combines primary and secondary research with in-house data resources and expert networks to generate strategic insights and analytics tools. The company differentiates itself through its tight life sciences specialization, its integration of consulting with proprietary analytics products, and its global client base and venture arm. Its goal is to speed up innovation in precision medicine and broaden access to it, supported by DeciBio Ventures which investments early-stage precision medicine companies.
Work here?Claim your company
Simplify's take
What believers are saying
- The November 6, 2026 portal launch converts research into subscription software.
- DeciBio's April 28, 2026 digital pathology report projects $2.1 billion by 2031.
- Its 2026 liquid biopsy report forecasted $17 billion by 2031, signaling strong demand.
What critics are saying
- DeciBio sells premium niche intelligence; enterprise buyers can replace it with internal teams.
- The portal depends on proprietary data collection; slower transcript growth weakens DeciChat quickly.
- If clients treat DeciChat as commoditized AI, DeciBio's subscription uplift collapses.
What makes DeciBio Consulting unique
- DeciChat unifies proprietary reports, DxBooks, trackers, and transcripts into cited answers.
- It owns 250-plus KOL transcripts and 1,600-plus DxBook entries across 15 markets.
- Carl Schoellhammer and Steve Beuchaw expanded advanced therapies and financial-services expertise in 2026.
Help us improve and share your feedback! Did you find this helpful?